Beyond HbA1c

Area of Science:

• Endocrinology and Metabolism
• Diabetes Management Technologies
• Clinical Biochemistry

Background:

• HbA1c, a common diabetes metric, has limitations in accurately reflecting glycemic control due to factors like anemia, renal disease, age, and ethnicity.
• HbA1c fails to capture glycemic variability, hypoglycemia, and weight changes, which are critical aspects of diabetes management and treatment outcomes.
• Patient surveys indicate dissatisfaction with current diabetes care, with a significant portion of time spent outside the target glucose range (70-180 mg/dL).

Framework:

• Continuous Glucose Monitoring (CGM) provides a more comprehensive understanding of glycemic patterns compared to traditional self-monitoring of blood glucose (SMBG) and HbA1c.
• The diaTribe Foundation meeting highlighted the potential of CGM in clinical practice for improving diabetes treatment and outcomes.
• Proposed glucose cut-off levels for hypoglycemia (<70 mg/dL), severe hypoglycemia (<54 mg/dL), hyperglycemia (>180 mg/dL), and serious hyperglycemia (>240 mg/dL) were discussed.

Implementation:

• CGM technology offers superior insights into glycemic excursions, avoiding potential misinterpretations associated with indirect HbA1c measurements.
• Integration of SMBG and CGM data is crucial for enhancing accuracy, detecting measurement errors, and improving patient and provider confidence in glucose readings.
• Development of data transmission and storage modalities for SMBG and CGM is essential for effective feedback and treatment adjustments.

Implications:

• CGM is crucial for developing improved clinical treatment approaches by providing multiple views of glycemic exposure patterns.
• Duration and severity of hypoglycemia may become important efficacy measures, shifting focus from solely safety outcomes.
• Regulatory bodies like the European Medicines Agency are considering reduced reliance on HbA1c, necessitating novel approaches in clinical practice and drug development.